LACTOLOGY FOUNDATION

ATC class A03CA02 (“clidinium and psycholeptics”) comprises fixed‑dose combinations of the synthetic anticholinergic antispasmodic clidinium with central nervous system depressant (psycholeptic) agents, used for functional gastrointestinal disorders such as peptic ulcer and irritable bowel syndrome (IBS).medpedia.framar+3

Pharmacological class and components

Clidinium is a synthetic anticholinergic (muscarinic antagonist) that exerts pronounced antispasmodic and antisecretory effects on the gastrointestinal tract, primarily by inhibiting muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. Psycholeptics in these combinations are typically benzodiazepines such as chlordiazepoxide, which decrease abnormal electrical activity in the brain and provide anxiolytic and sedative effects that modulate emotional factors contributing to gastrointestinal symptoms.kegg+4

Clidinium reduces gastric acid secretion and slows intestinal motility, which helps alleviate cramping, abdominal pain and other manifestations of functional GI motility disturbances. The psycholeptic component acts centrally to reduce anxiety, tension and visceral hypersensitivity, thereby complementing the peripheral antispasmodic action in patients whose symptomatology has a strong psychosomatic component.medicinenet+5

Therapeutic indications

Clidinium–psycholeptic combinations (e.g. chlordiazepoxide hydrochloride with clidinium bromide, marketed as Librax and similar products) are indicated as adjunctive therapy in peptic ulcer disease, IBS and enterocolitis. They may also be used to relieve colicky abdominal pain, diverticulitis‑associated spasms and abdominal cramps in other functional gastrointestinal disorders.drugbank+3

In routine practice these combinations target patients with abdominal pain, spasms, bloating, and altered bowel habits when a functional etiology is suspected and significant anxiety or emotional distress is present. They are generally reserved for short‑term use as part of a broader regimen that can include acid suppression, dietary modification and psychological support.medlineplus+2

Dosage and administration

Oral fixed‑dose capsules containing clidinium bromide and chlordiazepoxide hydrochloride are usually administered three to four times daily, before meals and at bedtime. Typical adult regimens involve one to two capsules every 6–8 hours, with the exact dose and duration individualized according to symptom severity, comorbidities and response, following medical prescription.medpedia.framar+2

Treatment should employ the lowest effective dose for the shortest possible duration to limit benzodiazepine‑related dependence and anticholinergic adverse effects, and dose adjustments are considered in frail, elderly or hepatically impaired patients. Because of the CNS depressant component, gradual tapering rather than abrupt discontinuation is advisable after prolonged use to reduce withdrawal or rebound phenomena.medsafe+2

Contraindications and precautions

These combinations are contraindicated in patients with known hypersensitivity to clidinium, the psycholeptic (e.g. chlordiazepoxide) or excipients. Additional contraindications and cautions arise from the anticholinergic component, including narrow‑angle glaucoma, urinary retention, severe prostatic hypertrophy, paralytic ileus and certain obstructive gastrointestinal conditions, where reduced motility or increased pressure could worsen the underlying disease.wikipedia+4

Benzodiazepine‑containing combinations are contraindicated or require extreme caution in patients with myasthenia gravis, severe respiratory insufficiency, sleep apnea or significant hepatic impairment, due to risks of profound sedation, respiratory depression and drug accumulation. Concomitant use with other CNS depressants (opioids, alcohol, sedative antihistamines, hypnotics) can synergistically increase sedation and respiratory suppression, so such combinations should generally be avoided or carefully supervised.medicinenet+2

Adverse effects and toxicological profile

Anticholinergic effects from clidinium include dry mouth, blurred vision, tachycardia, constipation and urinary retention, reflecting peripheral muscarinic blockade. At higher exposures, more serious effects such as paralytic ileus, exacerbation of glaucoma and confusion (especially in older adults) can occur.drugbank+2

The psycholeptic (chlordiazepoxide) contributes dose‑dependent sedation, dizziness, impaired coordination, cognitive slowing and, with prolonged use, risk of tolerance, dependence and withdrawal symptoms. In overdose or in susceptible patients, profound CNS depression, respiratory compromise, hypotension and, rarely, coma may develop, requiring emergency care and supportive measures and, in benzodiazepine toxicity, possible use of flumazenil under strict monitoring.medlineplus+1

Drug interactions

Clidinium and psycholeptics (A03CA02) show numerous clinically relevant interactions, including highly, moderately and minimally significant ones, as documented in interaction databases. Strong interactions involve additive CNS depression when combined with opioids, barbiturates, alcohol or other sedative/hypnotics, increasing risks of impaired consciousness and respiratory suppression.medpedia.framar+2

Anticholinergic load is increased by co‑administration with tricyclic antidepressants, antihistamines with antimuscarinic properties, antiparkinsonian anticholinergics and some antipsychotics, which can escalate peripheral and central anticholinergic toxicity. Pharmacokinetic interactions may arise with drugs that inhibit or induce hepatic metabolism of benzodiazepines (e.g. certain azole antifungals, macrolide antibiotics, antiepileptics), altering chlordiazepoxide plasma levels and necessitating dose adjustments.medsafe+3

Use in pregnancy

Clidinium‑containing combinations are generally not recommended in pregnancy, particularly during the first trimester, because of potential teratogenic risk and adverse fetal outcomes associated with benzodiazepines. Product information and regulatory guidance typically advise avoiding these combinations unless the expected maternal benefit clearly outweighs the potential risk to the fetus and alternative therapies are unsuitable.medicinenet+1

Benzodiazepine exposure in late pregnancy may lead to neonatal sedation, hypotonia, respiratory depression or withdrawal symptoms, while anticholinergic exposure could theoretically influence fetal autonomic function, so close obstetric and neonatal monitoring is necessary if use cannot be avoided. Overall, safer, better‑studied alternatives for gastrointestinal and anxiety symptoms are preferred in pregnant patients whenever possible.sps+3

Use in lactation (toxico‑lactological assessment)

Both clidinium and chlordiazepoxide can pass into breast milk and may cause infant sedation, poor feeding and reduced milk production, so clidinium‑psycholeptic combinations are generally considered unsuitable during breastfeeding. Product summaries explicitly warn that these capsules can sedate the breastfed infant and impair suckling, and that clidinium‑containing medications may decrease milk supply, likely due to antimuscarinic inhibition of parasympathetic pathways involved in lactation.healthbanks+2

From a toxicological‑lactological standpoint, the combination involves two risk components for the breastfed infant: anticholinergic GI and central effects from clidinium, and benzodiazepine‑mediated CNS depression from chlordiazepoxide, both of which may accumulate given repeated maternal dosing. Specialist breastfeeding guidance on GI antispasmodics recommends alternative agents with more favorable lactation safety profiles (e.g. hyoscine butylbromide, propantheline, peppermint oil, mebeverine, alverine), and emphasizes using compatible medicines at the lowest effective dose, timed around feeds, with infant monitoring for sedation, feeding difficulties and gastrointestinal disturbance.breastfeeding+4

Because of these risks, clidinium and psycholeptics (A03CA02) should generally be avoided in breastfeeding women, particularly with neonates or preterm infants, and reserved only for exceptional situations where benefit is compelling, duration is short, and close infant observation is feasible. Where maternal therapy for functional GI disorders is required, choosing non‑benzodiazepine, non‑anticholinergic or locally acting options, plus non‑pharmacological measures, is strongly preferable from a lactation safety perspective.torrentpharma+5

Regulatory status and access

Clidinium–psycholeptic combinations such as chlordiazepoxide/clidinium bromide carry ATC code A03CA02 and are classified as synthetic anticholinergic antispasmodics in combination with psycholeptics. They are prescription‑only medicines, reflecting their potential for serious adverse effects, dependence and clinically significant interactions and the need for careful patient selection and monitoring.atcddd.fhi+4

Regulatory documents describe them as “possibly effective” adjuncts in peptic ulcer and IBS rather than primary therapies, reinforcing their role as second‑line or supportive treatment rather than routine first‑choice agents. In many markets, use has declined with the advent of modern acid‑suppressive therapy and targeted treatments for functional GI disorders, further limiting their exposure in pregnant and lactating populations.kegg+2